Propranolol and breast cancer-a work in progress.

ABSTRACT: The non-selective beta-blocker propranolol is a leading candidate for repurposing as a novel anti-cancer agent. Emerging evidence, including human data, suggests that there are multiple mechanisms of action particularly relevant to breast cancer. This editorial reviews a number of recent studies that show it has anti-metastatic activity that warrants clinical investigation, including investigation as a potential perioperative therapy in breast cancer.

SUBMITTER: Pantziarka P 

PROVIDER: S-EPMC6027968 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature